Tempus AI, Inc. Common Stock (TEM.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS
Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.
Updated on 5 June 2026Deep analysis 5 June 2026
Russlan Ramdowar
Gemini 3.1 ProElon Musk AI
The Visionary FrameworkModel rating
Strong Buy
5-Year Return Est.
+334.5%
TEM.NASDAQ does not currently pay dividends
Historical prices and published forecast
- Observed price
- Published advisor forecast
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning
Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.
| Quarter | Forecast | Total return | Scenario |
|---|---|---|---|
| $54.9 | +5.0% | Initial post-Hormuz stabilization; BIOSECURE Act dynamics force pharma capital toward domestic data infrastructure. Tempus margin momentum recognized by smart money. | |
| $63.1 | +20.7% | End of year capital rotation into clear AI application winners with fundamental revenue, defying the hardware bubble. Gross margin expansion continues. | |
| $68.2 | +30.4% | Approaching cash-flow breakeven point. Q4 2026 earnings print validates the software-as-a-service licensing model over pure sequencing revenue. | |
| $75.0 | +43.5% | Positive FCF confirmation catalyst hits. The market abruptly rotates valuation from a speculative health-tech multiple to a monopoly data-infrastructure multiple. | |
| $81.7 | +56.4% | Major pharma R&D pipeline deals compound. The proprietary data flywheel accelerates as more hospital nodes come online. | |
| $89.9 | +72.0% | Escape velocity achieved. Cash generation allows for aggressive internal R&D expansion without touching the debt markets. | |
| $97.1 | +85.8% | Broader macro easing cycle begins to lift high-growth multiples. Tempus proves its agentic AI workflows drastically cut clinical trial timelines. | |
| $105 | +100.6% | FDA fast-track approvals for Tempus-assisted therapeutic discoveries validate the platform as a foundational drug-creation engine. | |
| $113 | +116.7% | Global expansion outside the US begins to scale, though carefully navigating geopolitical data-fencing laws. | |
| $126 | +140.5% | A blowout quarter driven by a massive multi-year enterprise license agreement with a top-3 pharma giant. | |
| $136 | +159.7% | Stable compounding phase. The market fully prices in the insurmountable physical moat of their integrated clinical-genomic dataset. | |
| $145 | +177.9% | New multi-modal capabilities are added to the OS, driving higher average revenue per hospital. | |
| $154 | +194.6% | Incremental margin expansion slows as they hit terminal gross margins around 80%, but absolute free cash flow continues to scale. | |
| $166 | +218.2% | Sector-wide pivot to AI-first drug discovery makes Tempus data access a mandatory utility for any serious biotech firm. | |
| $176 | +237.3% | Maturation phase begins. Revenue growth decelerates slightly from hyper-growth to durable, high-profit compounding. | |
| $187 | +257.5% | Healthcare budgets stabilize, accelerating the velocity of hospital integrations and hardware deployments at the edge. | |
| $196 | +275.4% | Tempus exercises pricing power on its data licensing, proving the inelasticity of demand from desperate pharma pipelines. | |
| $206 | +294.1% | The TAM expands from oncology into cardiology and neuro-degenerative diseases, opening a massive secondary growth curve. | |
| $216 | +313.8% | First-principles dominance confirmed. They are the de facto operating system for biological data processing. | |
| $227 | +334.5% | End of horizon. Tempus stands as a mega-cap healthcare infrastructure monopoly, unassailable by pure software challengers. |
1. Investment Thesis — Base Case
The base case is a paradigm-shifter achieving escape velocity. Tempus is building the structural OS for precision medicine, with revenue crossing $1B and gross margins ripping to 69%. The cash burn is entirely temporary, subsidizing the creation of an unassailable data monopoly that will generate massive software-like cash flows as pharma becomes utterly dependent on it.
- The physical data moat is insurmountable for pure-play software competitors.
- The BIOSECURE Act acts as an artificial accelerant for their domestic pipeline.
- The unit economics prove this is a data-licensing business, not a low-margin lab.
- Escaping cash-burn within 18-24 months will trigger a violent repricing as legacy analysts realize the physics of the business model.
- At a $9B market cap, the multiple is absurdly cheap for a monopoly asset compounding at +83% YoY. The implied market cap of $18B-$25B over the horizon is easily justifiable given the $1T+ TAM of oncology and pharmaceutical R&D.
2. Scenarios & Signals
2.1. Bull Case
In the bull case, Tempus achieves escape velocity ahead of schedule and licenses a blockbuster de novo therapeutic asset, proving the platform's ultimate capability.
- Margin expansion hits 80% terminal velocity.
- A hyperscaler launches a bidding war to acquire the dataset.
- The TAM expands seamlessly from oncology into cardiology and neuro-degenerative diseases.
- Implied valuation approaches $30B-$40B as it becomes the absolute standard for biological computation.
2.2. Bear Case
In the bear case, the macro cost of capital and inference-compute inflation drown the company before they can cross the profitability threshold.
- DOGE slashes Medicare reimbursement for sequencing.
- Hospitals, crushed by stagflation, halt IT integrations.
- Tempus is forced into a highly dilutive capital raise in a 5% rate environment, permanently impairing shareholder equity.
2.3. Behavioral Alpha Signals
Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.Expected Volatility Regime
Greed and Fear Index
Cycle Position
The narrative is building and informed capital is paying attention.
What does Media Tell? (Crowd Consensus)
The crowd fundamentally misunderstands the physics of AI in biology. Wall Street analysts look at the trailing net income of -$245M and dismiss Tempus as a zero-interest-rate artifact or just another high-cash-burn diagnostics lab masquerading as an AI company to catch a multiple. The media anchors to generic 'precision medicine' buzzwords without understanding the business model, assuming Tempus is easily replaceable by the next Silicon Valley startup that wraps an OpenAI API around a medical PDF reader.
What Crowds Get Wrong? (Alpha/Value Gap)
The variant perception is that in the LLM era, compute and algorithms are commodities; the only durable moat is proprietary, multimodal, physical-world data. Tempus isn't a lab; it is a data monopoly. You cannot scrape patient genomes from Reddit. By integrating directly into hospital EMRs and physically sequencing tumors, Tempus has built an insurmountable, federally compliant data flywheel just as the BIOSECURE Act forces pharma to onshore their data pipelines. The market is pricing a lab; they should be pricing an operating system.
When will Value Gap Repricing Happen? (Repricing Catalyst)
The Alpha Gap closes when Tempus prints its first structurally positive Free Cash Flow quarter, mathematically disproving the 'perma-burn' thesis. Expect this within the next 4-6 quarters. Once FCF is positive, the valuation abruptly rotates from a speculative health-tech multiple to a monopoly data-infrastructure multiple.
How is Asset Influenced by Macro Regime?
The macro wind is highly polarized. Punitive interest rates and the Warsh-era Treasury squeeze punish cash-burning equities severely. However, the geopolitical fragmentation specifically the BIOSECURE Act and the US-China biotech decoupling acts as a massive tailwind, forcing capital into domestic, sovereign-secure data platforms.
3. Positive & Negative Factors, Risks & Opportunities
3.1. Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| THE Physical DATA Monopoly | Competitive Positioning | +80% | +50% | If you evaluate this company on trailing P/E ratios, you should find a different profession. AI algorithms are becoming a commodity. What matters is the training substrate. Tempus holds the largest proprietary, multimodal clinical-genomic dataset in the US. You cannot scrape this from the internet; you have to build physical infrastructure inside hospitals to extract it. This is an insurmountable barrier to entry for Silicon Valley tourists trying to enter biotech. They are buying a monopoly, not subsidizing a unit loss. |
| UNIT Economics Inflection | Operational Efficiency | +45% | +60% | Gross margins ripped from 54% to near 70% in one year. Operating margin improved by 8000 basis points. The software-as-a-service and data-licensing elements are overwhelming the physical sequencing costs. They are mathematically approaching escape velocity. The unit economics are entirely separated from legacy diagnostic lab models, proving the physics of their zero-marginal-cost data flywheel. |
| Biosecure ACT Tailwind | Regulatory | +35% | +25% | With Washington hard-fencing the biotech supply chain away from China, Tempus is the default strategic winner. Pharma companies can no longer outsource genomic sequencing and data structuring to BGI or Wuxi without catching federal hell. Tempus is the onshore sovereign-data beneficiary. This is forced capital reallocation by the US government, and Tempus is standing exactly where the money has to flow. |
| Pharma Desperation Pipeline | Sector And Industry | +30% | +20% | Big Pharma is facing massive patent cliffs and catastrophic R&D failure rates. They are panicked. They have no choice but to pay Tempus for digital-twin trial data and AI-driven target discovery to salvage their pipelines. This inelastic demand from desperate incumbents provides a perpetual bid for Tempus's data licensing. |
Near-certain negative forces
Top Frictions / Headwinds
Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Austerity AND Medicare Squeeze | Regulatory | -25% | -30% | With DOGE slashing the federal budget, Medicare reimbursement rates for next-generation sequencing face structural headwinds. If the government stops paying for the clinical tests that generate the raw data, the front-end of the Tempus flywheel slows down dramatically. |
| Capital COST Gravity | Macroeconomic And Macrofinancial | -20% | -10% | Warsh's Fed is keeping the cost of capital punitively high. Even though Tempus is approaching cash-flow breakeven, any execution stumble will be mercilessly punished by a bond market yielding 5% on risk-free paper. Cash-burners face zero gravity assistance in this macro regime. |
| Compute COST Inflation | Operational Efficiency | -15% | -25% | Running multimodal agentic AI across massive genomic datasets burns compute. With the Hormuz shock driving up energy prices and Nvidia/Taiwan bottlenecks keeping AI hardware expensive, Tempus faces structural pressure on its cloud and inference OPEX. If token-economics break down, their gross margin expansion hits a brick wall. |
| Hospital Margin Collapse | Sector And Industry | -15% | -15% | Stagflation and energy costs are crushing hospital operating margins. Since Tempus relies on clinical partnerships and health-system IT integration to extract data, broke hospitals mean delayed deployments and slower data acquisition. You can't digitize biology if the hospital can't keep the lights on. |
3.2. Risks & Opportunities
Plausible downside scenarios
Tail Risks
Less likely downside scenarios that could materially hurt the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| DATA Exfiltration / Security Breach | 20% | -50% | A catastrophic state-sponsored hack breaches their genomic databases, triggering massive HIPAA liabilities, regulatory freezes, and a total loss of pharma trust. In the data monopoly business, losing the vault is an existential failure. |
| Reimbursement Policy NUKE | 15% | -40% | CMS entirely revokes broad coverage for broad molecular profiling in early-stage cancers to cut federal costs, wiping out the physical sequencing revenue that subsidizes the data aggregation. The flywheel goes into reverse. |
Plausible upside scenarios
Tail Opportunities
Less likely upside scenarios that could materially improve the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| DE NOVO Therapeutic Discovery | 15% | +80% | Tempus spins out or licenses an entirely novel, AI-discovered therapeutic asset that hits in Phase II clinical trials, proving the platform is a foundational drug-creation engine, not just a passive data vendor. This re-rates the TAM by 10x. |
| Hyperscaler Acquisition | 25% | +60% | A tech titan like Microsoft or Alphabet realizes they cannot win the biological AI race without proprietary data and outright buys Tempus at a massive premium to monopolize the healthcare AI layer. Compute is cheap; proprietary hospital data is priceless. |
5. References & Context
Search behavior, retained evidence, supplied context, and response token details.This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.
Context supplied to the model
Public-safe inputs retained with this immutable forecast publication.
- 01
Market data
inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
- 02
Global context in this run
Used
- 03
Fundamental data in this run
Used
- 04
Subject context
Equity-specific subject and market context
- 05
Global context
Standard global market and cross-asset context
- 06
Task framework
Standard investment-forecast task guidelines
- 07
Advisor framework
Elon Musk The Visionary
- 08
Forecast output requested
Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-04-10
Download Archived SnapshotCoverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10
- File size
- 73.5K bytes
- Words
- 9.8K words
- Characters
- 73.5K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Original published forecast
Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.
A consensus thesis is not available for this publication.